Yüksel Ürün shared a post on X:
“Multicancer Detection (MCD) tests use one blood sample to screen for multiple cancers.
- Potentially improves early detection, especially for cancers without effective screening.
- Benefits and harms are still unknown.
- Unlike conventional tests, the specific cancer organ is unknown, requiring broad diagnostics.
- In studies with 16,000+ participants, MCD identified early-stage cancers like pancreas, ovary, liver, and more.
- Sensitivity ranges from 27%-95%, lower for early-stage cancers.
- False negatives may reduce standard screening adherence.
- Trials needed to confirm accuracy, early detection effectiveness, and impact on overdiagnosis.”
Additional information.
Source: Yüksel Ürün/X
Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.